Edition:
United States

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

1.09USD
26 Jul 2017
Change (% chg)

$0.07 (+6.86%)
Prev Close
$1.02
Open
$1.03
Day's High
$1.16
Day's Low
$1.03
Volume
15,142
Avg. Vol
6,410
52-wk High
$1.73
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Casi Pharmaceuticals reports Q1 loss per share $0.03
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Casi Pharmaceuticals Inc :Casi Pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.03.Casi Pharmaceuticals Inc - as of March 31, 2017, Casi had cash and cash equivalents of $25.5 million.  Full Article

Casi Pharmaceuticals reports Q4 loss per share $0.05
Friday, 31 Mar 2017 07:00am EDT 

Casi Pharmaceuticals Inc : CASI Pharmaceuticals reports 2016 fourth quarter and full year financial results .Q4 loss per share $0.05.  Full Article

Casi Pharmaceuticals says up to 28.9 mln shares of co's common stock may be offered for sale by selling stockholders
Friday, 2 Dec 2016 04:48pm EST 

Casi Pharmaceuticals Inc :Says up to 28.9 million shares of co's common stock may be offered for sale by selling stockholders - SEC filing.  Full Article

Casi Pharmaceuticals reports third quarter 2016 results
Monday, 14 Nov 2016 07:00am EST 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports third quarter 2016 financial results .Q3 loss per share $0.03.  Full Article

Casi Pharmaceuticals Q2 loss per share $0.08
Monday, 15 Aug 2016 07:00am EDT 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.08.  Full Article

Casi Pharmaceuticals reports Q1 loss per share $0.04
Friday, 13 May 2016 07:16am EDT 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports first quarter 2016 financial results .Q1 loss per share $0.04.  Full Article

CASI Pharmaceuticals Inc receives EU orphan drug designation for the use Of ENMD-2076
Wednesday, 14 Oct 2015 07:00am EDT 

CASI Pharmaceuticals Inc:Says Oncology drug candidate, ENMD-2076, has received Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of hepatocellular carcinoma.Designation provides CASI with 10 years of market exclusivity in EU after ENMD-2076 receives marketing authorization there.  Full Article

CASI Pharmaceuticals Inc to Raise $25.1 Million in Private Placement of Common Stock and Warrants
Monday, 21 Sep 2015 07:00am EDT 

CASI Pharmaceuticals Inc:Announced that it has entered into definitive agreements for a $25.1 million financing led by a China investment fund manager affiliated largest shareholder, IDG-Accel China Growth Fund III, L.P.The Company agreed to sell a total of 20,658,434 shares of common stock, at $1.190 per share and a total of 4,131,686 warrants, representing a 20% warrant coverage, with a purchase price of $0.125 per whole warrant share.The warrants will become exercisable three months after issuance at $1.69 per share exercise price, and will expire three years from the date the warrants become exercisable.  Full Article